IMMUNOSCORE® Immunity Assessed - Personalized Treatment

A Novel Paradigm for Cancer

To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells.

A new paradigm, scientifically well established and cited in WHO* classification of Tumours Series 5th edition, relies on the assessment of the immune response as a new risk feature related to clinical outcomes of colon cancer patients.

Maximize patient survival rates with an assessment of the tumor immune response.

 

*The World Health Organization is not endorsing the Immunoscore® commercial assay.

Immunoscore®

Immunity assessed, Personalized treatment

Immunoscore® is a test, recently included within ESMO guidelines, that predicts the risk of relapse in patients with localized colon cancer thereby facilitating the chemotherapy decision-making process.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pagès et al, The Lancet 2018), Immunoscore® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

Discover how Immunoscore® is helping to predict the risk of Localized Colon Cancer recurrence in our short video.

How can Immunoscore® help patient management?

With localized colon cancer

Introducing Immunoscore® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help to facilitate:

  • Refinement of patient risk profiles by providing a greater prognostic value compared to traditional measurements.
  • Adjustment of treatment decisions and improved colon cancer patient management.
  • Optimization of adjuvant chemotherapy duration.
  • Personalization of patient follow-up.

Clinical Data and Clinical Utility

Role of Immunoscore in Colon and Rectal Cancer
Presentation by Prof. Claus-Henning Köhne at IGICC Congress
Watch testimonials from gastrointestinal oncologists around the world on how Immunoscore® is improving their daily practice here

How does Immunoscore® work?

The Immunoscore® is a tissue-based immune assay performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples of primary colon cancer intended to measure the host immune response at the tumor site.

In combination with standard clinicopathologic features, this digital diagnostic test informs adjuvant chemotherapy decision-making for patients with early-stage colon cancer.

Immunoscore® values are reported based on pre-defined cut-offs in 5 categorical scores (IS 0 to 4) and in 2 categories of recurrence risk: Immunoscore® Low (IS 0 &1) and Immunoscore® High (IS 2 to 4), with a higher Immunoscore® associated with a lower risk of recurrence (Pagès F et al. The Lancet 2018, Sinicrope F et al. JNCI Cancer Spectrum 2020, Pages et al. Ann Oncol. 2020).

In validation studies of stage III colon cancers, only Immunoscore® High patients experienced a significant therapy benefit (Pages et al. Ann Oncol. 2020, Mlecnik et al. J Clin Oncol.2020).

Measuring infiltration

A personalized Immunoscore® in two categories is provided and sent 10 working days after receipt of specimen for an informed and shared therapeutic decision-making.

The test is CE-IVD marked for Europe and performed as a CLIA service in our laboratories in Marseille, France and Richmond, Virginia.

Immunoscore worlflow



How to Order

Your contact:


HalioDx

Oncologists and patients are invited to contact HalioDx which markets and distributes Immunoscore® assay in your country.


Luminy Biotech Entreprises
163 Avenue de Luminy
13288 Marseille Cedex 9
FRANCE

Phone: +33 (0) 4 91 29 30 90

 www.haliodx.com

 contact customer service by mail



Find out more about Immunoscore® contact us

Resources


#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Brochure Immunoscore® in Localized CC (CE/IVD version)

For Healthcare Professionals (CE/IVD version)

#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Leaflet Immunoscore® in Stage III Colon Cancer

For Healthcare Professionals (English version)

#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Leaflet Immunoscore® in Stage II Colon Cancer

For Healthcare Professionals (English version)

#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Leaflet Immunoscore® in High-risk Stage II Colon Cancer

For Healthcare Professionals (English version)

#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Brochure Immunoscore® in Localized CC (CLIA US version)

For Healthcare Professionals (CLIA US version)

#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (English)

#Immunoscore® Colon
Video

#video | Jan. 2021

Dr Mellor, Malaysia, explains why and how he is using immmunoscore in Stage III colon cancer patients
#Immunoscore® Colon
Video

#video | Dec. 2020

Professor Yoshino, KOL in Asia region, talk about Immunoscore
#Immunoscore® Colon
Poster

#poster | Nov. 2020

ASCO Quality Care Symposium on October 9-10, 2020

Impact of Immune Assessment with Immunoscore® on Patterns of Care In Stage II Colon Cancer

#Immunoscore® Colon
Video

#video | Oct. 2020

Dr Tony Dhillon (UK) presenting Immunoscore at the Digestive Cancers Europe Scientific Update: Role of the Immune Response in Early Stage Colorectal Cancers
#Immunoscore® Colon
Video

#video | Oct. 2020

Testimonial: Dr Su Pin Choo (Curie Oncology, Singapore) on the utility of Immunoscore in early stage Colon Cancer
#Immunoscore® Colon
Video

#video | Oct. 2020

Managing colorectal cancer patients in the COVID-19 era with Drs Benjamin Weinberg (USA), Matías Chacón and Juan Manuel O’Connor (both Argentina)
#Immunoscore® Colon
Publication

#publication | Sep. 2020

Mlecnik B Bifulco C, Bindea G, et al.

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

J Clin Oncol.

#Immunoscore® Colon
Publication

#publication | Aug. 2020

El Sissy C, Kirilovsky A, Van den Eynde M et al.

A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Clin Cancer Res

#Immunoscore® Colon
Publication

#publication | Aug. 2020

F Pages, J Taieb, P Laurent-Puig, and J Galon

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

OncoImmunology

#Immunoscore® Colon
Publication

#publication | Aug. 2020

Bruni D, K Angell H and Galon J

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Nature Reviews Cancer

#Immunoscore® Colon
Video

#video | Jul. 2020

Immunoscore® highlights at ESMO GI. Presentations of Dr Le Bagousse and Jérôme Galon, PhD
#Immunoscore® Colon
Publication

#publication | Jul. 2020

A Lanzi,F.A Sinicrope, A.B Benson, and J Galon

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

OncoImmunology

#Immunoscore® Colon
Publication

#publication | Jun. 2020

A Lanzi,F Pages, C Lagorce-Pages, and J Galon

The consensus immunoscore: toward a new classification of colorectal cancer

OncoImmunology

#Immunoscore® Colon
Publication

#publication | Jun. 2020

O’Connor JM, Esteso F & Chacón M

Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine

Future Medicine

#Immunoscore® Colon
Video

#video | Jun. 2020

Testimonial: Dr Juan Manuel O’Connor (Instituto Alexander Fleming in Buenos Aires, Argentina) on the use of Immunoscore in routine practice in managing early Colon Cancer
#Immunoscore® Colon
E-news

#e-news | Jun. 2020

Factsheet Immunoscore® & COVID-19 Colon Cancer Guidelines
#Immunoscore® Colon
Poster

#poster | May. 2020

Poster presented at ASCO20 Virtual Scientific meeting#ASCO20

Immunoscore is the most powerful parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients Abstract 4105

#Immunoscore® Colon
Publication

#publication | May. 2020

Marliot F, Chen X, Kirilovsky A et al.

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

BMJ

#Immunoscore® Colon
E-news

#e-news | May. 2020

Expert Opinion: The Role of Microbiota and its Impact on the Tumor Microenvironment in Colorectal Cancer | Dr Benjamin A. Weinberg, MD, Oncologist in Georgetown, Washington DC
#Immunoscore® Colon
E-news

#e-news | Apr. 2020

Expert Opinion: Immunity and cancer | Dr Angela Alistar, MD, Oncologist in Morristown, NJ
#Immunoscore® Colon
Publication

#publication | Apr. 2020

Pages F, Andre T, Taieb J et al.

Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study

Annals of Oncology

#Immunoscore® Colon
Publication

#publication | Apr. 2020

Sinicrope F, Shi Q, Hermitte F et al.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

JNCI Cancer Spectrum

#Immunoscore® Colon
Publication

#publication | Mar. 2020

Blair H

Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer

Molecular Diagnosis & Therapy volume

#Immunoscore® Colon
Video

#video | Mar. 2020

Franck Pagès, MD, PhD, on Selecting Patients With Advanced Colon Cancer for Treatment
#Immunoscore® Colon
Poster

#poster | Jan. 2020

Poster presented at Gastro Intestinal Symposium #GI20

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (3 vs 6 months) in the prospective IDEA France cohort study

#Immunoscore® Colon
Publication

#publication | Jan. 2020

Pagès F, Kirilovsky A, Mlecnik B et al.

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Journal of Clinical Oncology

#Immunoscore® Colon
Brochure

#brochure | Sep. 2021

Brochure Immunoscore® in Localized Colon Cancer - SPANISH

For Patients & Caregivers (Spanish)

#Immunoscore® Colon
Video

#video | Sep. 2019

Webinar Immunoscore®: IDEA France study results in Stage III Colon Cancer - Sept. 19, 2019 | Franck Pagès, Eric Van Cutsem
#Immunoscore® Colon
Publication

#publication | Aug. 2019

Angell HK, Bruni D, Barrett JC et al.

The Immunoscore: Colon Cancer and Beyond.

Clin Cancer Res.

#Immunoscore® Colon
Poster

#poster | Jul. 2019

Poster presented at ESMO GI 2019

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

#Immunoscore® Colon
Video

#video | Jun. 2019

Extract of an interview by Cancer.fr of Professor Thierry André, on Immunoscore® in the IDEA France study (in French)
#Immunoscore® Colon
Video

#video | Jun. 2019

Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®
#Immunoscore® Colon
Poster

#poster | Jun. 2019

Poster presented at ASCO 2019

Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

#Immunoscore® Colon
Publication

#publication | May. 2019

Pages F, Andre T, Taieb J et al.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of Clinical Oncology

#Immunoscore® Colon
Video

#video | Apr. 2019

Dr. Fakih Discusses the Utility of Immunoscore® in CRC
#Immunoscore® Colon
Video

#video | Mar. 2019

Immunoscore® Webinar New data in Stage II Colon Cancer - March 21, 2019 | Jêrome Galon, PhD
#Immunoscore® Colon
Publication

#publication | Mar. 2019

Zeitoun G, Sissy CE, Kirilovsky A et al.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Chirurgia (Bucur).

#Immunoscore® Colon
Video

#video | Jan. 2019

Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video
#Immunoscore® Colon
Poster

#poster | Jan. 2019

Poster presented at Gastrointestinal Cancers Symposium 2019

Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

#Immunoscore® Colon
Poster

#poster | Dec. 2018

Poster presented at ESMO ASIA 2018

UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery

#Immunoscore® Colon
Poster

#poster | Dec. 2018

Poster presented at ESMO IO 2018

MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies

#Immunoscore® Colon
Poster

#poster | Nov. 2018

Poster presented at ESMO ASIA 2018

Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment

#Immunoscore® Colon
Publication

#publication | Oct. 2018

Angelova M, Mlecnik B, Vasaturo A et al.

Evolution of Metastases in Space and Time under Immune Selection.

Cell

#Immunoscore® Colon
Video

#video | Aug. 2018

Webinar on “Clinical utility of Immunoscore® in colon cancer” with Marc Van Den Eynde, MD, PhD | October 17, 2017
#Immunoscore® Colon
Video

#video | Aug. 2018

Dr Jerome Galon on the Prognostic Value of Immunoscore, Onclive - ASCO 2016
#Immunoscore® Colon
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Discussion on clinical cases
#Immunoscore® Colon
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Jérôme Galon, PhD
#Immunoscore® Colon
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Stanley Hamilton, MD
#Immunoscore® Colon
Publication

#publication | May. 2018

Pagès F, Mlecnik B, Marliot F et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Lancet

#Immunoscore® Colon
Poster

#poster | Feb. 2018

Poster presented at ASCO GI 2018

Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)

#Immunoscore® Colon
Publication

#publication | Feb. 2018

Sinicrope F, Shi Q, Hermitte F et al.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

J Clin Oncol.

#Immunoscore® Colon
Publication

#publication | Jan. 2018

Mlecnik B, Van den Eynde M, Bindea G et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst.

#Immunoscore® Colon
Poster

#poster | Jun. 2017

Poster presented at ASCO 2017

Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]

#Immunoscore® Colon
Publication

#publication | May. 2017

Sinicrope F, Shi Q, Hermitte F et al.

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

J Clin Oncol.

#Immunoscore® Colon
Publication

#publication | May. 2017

Galon J, Mlecnik B, Marliot F et al.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

J Clin Oncol.

#Immunoscore® Colon
Poster

#poster | Nov. 2016

Poster presented at SITC 2016

Immunoscore® analytical performance

#Immunoscore® Colon
Publication

#publication | Sep. 2016

Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon.

Journal for ImmunoTherapy of Cancer

#Immunoscore® Colon
Publication

#publication | Aug. 2016

Kirilovsky A, Marliot F, El Sissy C et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Int Immunol.

#Immunoscore® Colon
Publication

#publication | Mar. 2016

Mlecnik B, Bindea G, Angell HK et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Immunity

#Immunoscore® Colon
Publication

#publication | Feb. 2016

Mlecnik B, Bindea G, Kirilovsky A et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med.

#Immunoscore® Colon
Publication

#publication | Feb. 2011

Mlecnik B, Tosolini M, Kirilovsky A et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Journal of Clinical Oncology

#Immunoscore® Colon
Publication

#publication | Sep. 2006

Galon J, Costes A, Sanchez-Cabo F et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Science

Contact us

 
   

By subscribing to our newsletter, you accept to receive information on our news and events by email. You can unsubscribe any time by clicking on the unsubscribe link at the bottom of our newsletters, or by sending us an unsubscribe request at privacy(at)haliodx(dot)com.


Fields marked with an asterisk (*) are required!

The information about you collected through this form is used by HalioDx to handle your request. Fields with an asterisk are mandatory. Otherwise, your request for information cannot be processed.
Your data will be processed by HalioDx authorized services, and might be transmitted to external service providers processing your data on behalf of HalioDx. For more information on protection mechanisms implemented, please contact the data Protection Officer: privacy(at)haliodx(dot)com.

As HalioDx contacts, your personal data are stored in our database system as long as your subscription to the newsletter or email services is active. Any recipient may request at any time to be removed from our contact database by writing an email to privacy(at)haliodx(dot)com with “I wish to be removed from your contact Database” in your subject line and we will comply with that request.

HalioDx newsletter subscription


Join our newsletter and be the first to get notified on new updates.


× Hide this popup.